Navigation Links
Test Helps Identify Patients with Breast Cancer

A test that measures the amounts of two members of the same protein family - one of which appears to act as an oncogene // , and the other as a tumor suppressor - helps identify patients with breast cancer who will likely benefit from chemotherapy and those who won’t, according to researchers.

The test, known as OncoPlan?, is already commercially available, and studies have shown that it can predict the aggressiveness of the patient’s tumor and the relative risk of disease recurrence following surgery in breast, colon and gastric cancers. Now, researchers in the U.S. and Canada have studied whether it also can help identify breast cancer patients who would benefit most from chemotherapy.

Results were presented at the first meeting on Molecular Diagnostics in Cancer Therapeutic Development, organized by the American Association for Cancer Research.

OncoPlan measures two forms of Shc protein, which are known to drive the formation of protein complexes involved in signal transduction pathways and have been found to be involved in many of the pathways important to development of aggressive cancer. These two forms have a “push pull” relationship with each other: tyrosine-phosphorylated (PY)-Shc helps drive these dangerous cell pathways, but p66 Shc, after initial stimulation, works to inhibit the very growth pathway the other Shc proteins promote.

“This may be one mechanism whereby normal cells prevent runaway growth,” said the study’s lead author, A. Raymond Frackelton, Jr., Ph.D., a Brown University associate professor, staff scientist at Roger Williams Medical Center and Vice President of Research at Catalyst Oncology, which is marketing OncoPlan. “Perhaps more importantly, aggressive cancer cells must endure oxidative stress—stress that in normal cells triggers p66 Shc to cause cellular suicide,” he said. “Tumor cells, then, may have both growth and survival advantages if p66 Shc levels are low.”

Chemotherap y-mediated killing of tumor cells, however, does not require p66 Shc, Frackelton said, suggesting that patients whose tumor cells have low p66 Shc might respond well to chemotherapy. To test this idea, the researchers looked at the Shc proteins in tumors from 2,380 women from British Columbia who were diagnosed with invasive breast cancer, 717 of whom received chemotherapy as part of their initial treatment.

They found that, indeed, patients who had low levels of p66 Shc and did not receive chemotherapy had very poor outcomes. If similar patients received chemotherapy, however, their chances of relapsing and dying from their disease were reduced by two-fold or more, said Frackelton. Conversely, women with high levels of p66 Shc had a much higher likelihood of surviving their disease, but appeared to derive no benefit from chemotherapy, he said.

Possible additional associations between PY-Shc and chemotherapy benefit has not yet been fully explored, Frackelton said. “But even at this point, the results are very exciting because, with further validation in clinical trials, OncoPlan, which is already being used to predict disease aggressiveness, will help to ensure that individual patients receive the most beneficial therapies,” he said.


Related medicine news :

1. Antibiotics Helps Autism
2. Serum Progesterone Helps Stratify Ectopic Pregnancy Risk
3. Prescription Drug - Helps People Stop Smoking
4. New Drug PP188 Helps Sickle Cell Disease
5. Red Wine Helps Fight Heart disease
6. Creatine Helps Strengthen Older Men
7. Cholesterol Drug Helps After Angioplasty
8. Virus Helps Remove Brain Cancer
9. Eating Fish Helps the Heart
10. Antidepressant Helps Relieve Hot Flashes
11. Epilepsy Drug Helps Diabetic Nerve Damage
Post Your Comments:

(Date:11/30/2015)... ... November 30, 2015 , ... In an effort to ... Word of Life Christian Church of Flint, MI, hosted a family-oriented evening themed ... ton pile of candy dubbed “Candy Mountain”. , A Forever Recovery, a holistic ...
(Date:11/30/2015)... ... November 30, 2015 , ... During ... fundraising campaign to raise funds for its research, education, support, and advocacy efforts. ... organization’s annual funding. , The Mesothelioma Applied Research Foundation, which also goes by ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... Catalyst continuing education course in Dallas, TX, on January 29 and 30, 2016. ... to improve the functions of their practices, to learn how to better succeed ...
(Date:11/30/2015)... ... 2015 , ... HemoTreat™ has announced that the company has ... its website. , “Our goal is simple:” says Michael Blasco, HemoTreat’s Chief Communication ... chart and ingredient list allows our customers to quickly see why, and how, ...
(Date:11/30/2015)... Scotch Plains, NJ (PRWEB) , ... November 30, ... ... is their top choice for innovative, patient centered orthopedic care. Led by ... Regardless of your injury or chronic condition, the team at Advocare Orthopedic & ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... 30, 2015  Hanger, Inc. (NYSE: HGR ) ... the terms of its previously announced consent solicitation (as ... $200,000,000 aggregate principal amount 7⅛% Senior Notes due 2018 ... consent fees payable pursuant to the Consent Solicitation, (ii) ... (iii) the expiration date of the Consent Solicitation.    ...
(Date:11/30/2015)... , Belgium , Nov. 30, 2015 ... sciences company focused on developing blood-based diagnostic tests for a ... the Company will present at the LD Micro Conference, which ... Los Angeles, CA. Attending from VolitionRx will be ... Scott Powell , Vice President of Investor Relations. ...
(Date:11/30/2015)... BOSTON , November 30, 2015 /PRNewswire/ ... potential new medicines directed at up to 10 G ... --> PFE ) to research and develop potential ... receptor (GPCR) targets across multiple therapeutic areas. --> ... discovery and development company and wholly-owned subsidiary of Sosei ...
Breaking Medicine Technology: